Schonfeld Strategic Advisors’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-30,000
Closed -$1.92K 2970
2022
Q4
$1.92K Hold
30,000
﹤0.01% 2425
2022
Q3
$2K Hold
30,000
﹤0.01% 2824
2022
Q2
$3K Buy
+30,000
New +$6.2K ﹤0.01% 2380

Schonfeld Strategic Advisors's BIOTW Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 30,000 shares — an estimated $1.92K sold.

Schonfeld Strategic Advisors first reported a position in BIOTW in Q2 2022 and held it in 3 quarters. The position peaked at $3K in Q2 2022. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

  • Schonfeld Strategic Advisors reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 30,000 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $1.92K.
  • Schonfeld Strategic Advisors first reported a position in Biotech Acquisition Company Warrant in Q2 2022 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Biotech Acquisition Company Warrant position peaked at $3K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.